Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Qiagen ( (QGEN) ).
QIAGEN N.V. disclosed that The Stephen H. Rusckowski Living Trust, associated with a member of the company’s supervisory body, purchased common shares on the open market. The transaction, executed on the NYSE on May 19, 2026, involved an aggregated consideration of about $1.01 million at a price of $34.5213 per share, signaling insider confidence that may be closely watched by investors and governance-focused stakeholders.
The most recent analyst rating on (QGEN) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a Netherlands-based life sciences company focused on molecular diagnostics and sample preparation technologies. Its products support clinical testing, academic research, and pharmaceutical development, and the shares are listed on several European exchanges as well as the NYSE, reflecting a broad international investor base.
Average Trading Volume: 2,065,981
Technical Sentiment Signal: Sell
Current Market Cap: $7.23B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.